No Mercy / No Malice: Corporate Ozempic

GLP-1 Analogy

Scott Galloway uses the analogy of GLP-1 drugs to explain the transformative impact of AI on corporate behavior. He suggests that just as these drugs suppress cravings, AI reduces the need for hiring, creating a new corporate landscape where efficiency trumps expansion 1. This analogy highlights the reluctance of early adopters to admit their use of AI, similar to the hesitation around GLP-1 drugs.

If you want to understand how AI is reshaping business, picture it as the other massive innovation of our time, GLP one drugs.

--- Scott Galloway

Galloway points out that both innovations exacerbate existing inequities, benefiting the affluent before broader societal gains are realized 1.

   

Corporate Growth

The relentless pursuit of growth in corporations is likened to steroid use, where AI acts as a performance-enhancing drug. Galloway describes how companies like Nvidia have skyrocketed in value, akin to athletes on steroids, by leveraging AI to boost productivity without increasing workforce size 2. This approach creates a paradox where growth is achieved with fewer employees, challenging traditional business narratives.

Nvidia GPU's are legal performance enhancing drugs for corporations.

--- Scott Galloway

He emphasizes the need for businesses to focus on output rather than input, suggesting that true growth comes from efficiency rather than mere expansion 2.